Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Oncol Rep ; 29(4): 1453-8, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23404437

RESUMEN

Gastric cancer is one of the most common and lethal malignancies worldwide. Bone metastases in gastric cancer are less common than in other solid tumors, but when they occur the prognosis is generally poor. Increased osteoclastogenesis and osteoclast activity are common features in bone metastases caused by different osteotropic cancer. We investigated osteoclastogenesis and its mechanisms in gastric cancer by enrolling 31 newly diagnosed gastric cancer patients and 45 healthy controls. We studied in vitro osteoclastogenesis in the peripheral blood mononuclear cell cultures of patients and controls, showing spontaneous osteoclastogenesis for half of the patients. This osteoclastogenesis was RANKL- and TNF-α-independent. We analyzed primary tumor and bone metastatic tissues of gastric cancer for the expression of genes involved in osteoclastogenesis. The expression of transforming growth factor-ß (TGF-ß), osteoprotegerin (OPG), IL-7 and dickkopf-1 (DKK-1) was higher in primary tumors than in bone metastases. RANKL was not detectable in primary tumor or in bone metastatic tissue. The serum RANKL level was significantly higher in healthy controls than in patients, and it was not related to osteoclastogenesis, thereby suggesting that RANKL is not involved in the bone metastatic mechanisms in gastric cancer. We hypothesized a role of RANKL in angiogenesis, thus we compared the serum levels of RANKL to those of VEGF, since VEGF is directly related to angiogenesis. Different from RANKL, the VEGF serum levels were higher in gastric patients than in controls, suggesting a block of the angiogenesis inhibition due to RANKL. RANKL and VEGF serum levels were not predictive of overall survival in our cohort of gastric patients.


Asunto(s)
Neoplasias Óseas/sangre , Neoplasias Óseas/secundario , Ligando RANK/sangre , Neoplasias Gástricas/sangre , Anciano , Neoplasias Óseas/patología , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Péptidos y Proteínas de Señalización Intercelular/sangre , Interleucina-7/sangre , Leucocitos Mononucleares/citología , Linfotoxina-alfa/sangre , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neovascularización Patológica/sangre , Osteoclastos/citología , Osteoclastos/metabolismo , Osteoprotegerina/sangre , Neoplasias Gástricas/genética , Neoplasias Gástricas/patología , Factor de Necrosis Tumoral alfa/sangre , Factor A de Crecimiento Endotelial Vascular/sangre
2.
Eur Spine J ; 18 Suppl 1: 109-14, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19468760

RESUMEN

Emisacrectomy is a challenging surgery in the treatment of tumours that affect the sacrum. Authors report their experience in 11 cases affected by tumours of the sacrum (9 chordomas, 1 ependymoma, 1 monostotic bladder metastasis) operated on at the Orthopaedic Department of A.S.O S. Giovanni Battista Molinette in Turin, Italy, from 1998 through 2005 discussing planning surgery, level of osteotomy, functional and oncological results and complications of the treatment at a median follow-up of 5 years (range 2-9), describing the surgical and medical teaching learned from the treatment of these patients. Despite the potential complications, emisacrectomy can be performed successfully and is an important procedure in the treatment of sacral tumours.


Asunto(s)
Neoplasias Óseas/cirugía , Procedimientos Neuroquirúrgicos/métodos , Osteotomía/métodos , Sacro/cirugía , Anciano , Neoplasias Óseas/patología , Neoplasias Óseas/secundario , Carcinoma/secundario , Carcinoma/cirugía , Cordoma/diagnóstico por imagen , Cordoma/patología , Cordoma/cirugía , Ependimoma/diagnóstico por imagen , Ependimoma/patología , Ependimoma/cirugía , Femenino , Estudios de Seguimiento , Humanos , Plexo Lumbosacro/patología , Plexo Lumbosacro/cirugía , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/patología , Complicaciones Posoperatorias/fisiopatología , Cuidados Preoperatorios , Radiografía , Procedimientos de Cirugía Plástica/métodos , Estudios Retrospectivos , Sacro/patología , Tiempo , Resultado del Tratamiento , Neoplasias de la Vejiga Urinaria/patología
3.
World J Gastroenterol ; 11(45): 7131-5, 2005 Dec 07.
Artículo en Inglés | MEDLINE | ID: mdl-16437659

RESUMEN

AIM: To investigate the seroprevalence of Helicobacter pylori (H pylori) infection and its more virulent strains as well as the correlation with the histologic features among patients who had undergone surgery for gastric cancer (GC). METHODS: Samples from 317 (184 males, 133 females, mean age 69+/-3.4 years) consecutive patients who had undergone surgery for gastric non-cardia adenocarcinoma were included in the study. Five hundred and fifty-five (294 males, 261 females, mean age 57.3+/-4.1 years) patients consecutively admitted to the Emergency Care Unit served as control. Histological examination of tumor, lymph nodes and other tissues obtained at the time of surgery represented the diagnostic "gold standard". An enzyme immunosorbent assay was used to detect serum anti-H pylori (IgG) antibodies and Western blotting technique was utilized to search for anti-CagA protein (IgG). RESULTS: Two hundred and sixty-one of three hundred and seventeen (82.3%) GC patients and 314/555 (56.5%) controls were seropositive for anti-H pylori (P<0.0001; OR, 3.58; 95%CI, 2.53-5.07). Out of the 317 cases, 267 (84.2%) were seropositive for anti-CagA antibody vs 100 out of 555 (18%) controls (P<0.0001; OR, 24.30; 95%CI, 16.5-35.9). There was no difference between the frequency of H pylori in intestinal type carcinoma (76.2%) and diffuse type cancer (78.8%). Intestinal metaplasia (IM) was more frequent but not significant in the intestinal type cancer (83.4% vs 75.2% in diffuse type and 72.5% in mixed type). Among the patients examined for IM, 39.8% had IM type I, 8.3% type II and 51.9% type III(type III vs others, P = 0.4). CONCLUSION: This study confirms a high seroprevalence of H pylori infection in patients suffering from gastric adenocarcinoma and provides further evidence that searching for CagA status over H pylori infection might confer additional benefit in identifying populations at greater risk for this tumor.


Asunto(s)
Adenocarcinoma/complicaciones , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Intestinos/patología , Neoplasias Gástricas/complicaciones , Adenocarcinoma/etiología , Adenocarcinoma/cirugía , Anciano , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Estudios de Casos y Controles , Femenino , Infecciones por Helicobacter/inmunología , Helicobacter pylori/inmunología , Humanos , Italia/epidemiología , Masculino , Metaplasia , Persona de Mediana Edad , Estudios Seroepidemiológicos , Neoplasias Gástricas/etiología , Neoplasias Gástricas/cirugía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA